top of page
30abbf_80cbda8aa51445e28421bf1c4f0491a5~mv2.jpg

Expertise

VIA / cubeRBQM Performance
cm_contry.png
78%
251023_cm_phase_x2.png
57%
19%
251023_cm_ta_x2.png
19%
By Therapeutic Area
KOR
JPN
Phase II
4%
Ophthalmology
17%
EU
5%
10%
5%
Phase III
10%
Gastroenterology
By Country
Phase IV
10%
Cardiovasular
OS/PMS
24%
Hematology
Medical Device
ETC.
By Phase
Endocrinology
19%
Allergology
5%
4%
Pulmonology
5%
10%
ETC.
eConsent Performance
Group 962.png
Group 961.png
43%
Group 960.png
15%
By Therapeutic Area
KOR
JPN
14%
14%
Phase I
Phase III
14%
43%
Ophthalmology
57%
15%
OS/PMS
14%
Cardiovascular
By Phase
Neurology
Food & supplementary
IIT
Allergology
43%
ETC.
By Country
14%
14%
2025.10 Now
Expertise_Gemini generation 2.png
스페로 웹사이트 - 파트너십.png
Execution Ecosystem

Spero strengthens its integrated execution capabilities across the entire clinical trial lifecycle through strategic collaborations with pharmaceutical and medical device sponsors, fellow CROs, and clinical sites.

Key fields of cooperation

  • Clinical operations (CRO service)
  • Patient recruitment & Engagement
  • Digital-Enabled DCT Operations
Site Management & Monitoring
Vaccines & Infectious disease
Dentistry
251023_op_x2.png
251023_phase_x2.png
PMS
3%
Phase IV
3%
mo_phase.png
tb_op2.png
tb_phase.png
tb_ta2.png
mo_ta.png
mo_op.png
Achievement

Spero started patient recruitment service in 2021 and has been accumulating achievements in various CRO service areas since it expanded its business to DCT in 2022.

Therapeutic Area & Phase

Experienced Staffs and Potential expertise

Spero is enhancing its expertise and operational efficiency for the successful execution of clinical trials

43%
251023_ta_x2.png
Ophthalmology
Gastroenterology
Endocrinology
Cardiovascular
Pulmonology
Hematology
5%
5%
8%
8%
11%
24%
By Therapeutic Area
By Phase
Others
Medical Device
IIT
OS
Phase I
Phase III
Phase II
3%
5%
14%
5%
14%
Neurology
11%
8%
5%
11%
Clinical Operation

Full Support Service

Spero supports all phases of clinical trials, and prioritizes customer requirements, and the safety of clinical trials

14%
14%
29%
31%
6%
6%
Statistics
Data Management
Medical Writing
Project Management
Site Startup
By Operation service

*Site Management : VIA/cubeRBQM service included.

3%
3%
PMS
Phase IV
Others
14%
bottom of page